ArticleScientific reports2020

Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin.

Andres M Arias Lorza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.